An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer.,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer.
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2020-01-06 , DOI: 10.1039/c9tb02284h
Zhanxia Zhang ₁ , Wei Cheng ₁ , Yongfu Pan ₁ , Lijun Jia ₁

Affiliation

Stimuli response or controlled release is a new research hotspot in nanomedicine; however, there is scarce research on organic nanomedicines with stimuli responses, which limits their practical biological applications. In addition, homoharringtonine (HHT) has been used as an effective anticancer agent, but reducing its toxicity and side effects is an urgent problem to be solved. Herein, an EGFR (epidermal growth factor receptor) aptamer-modified HHT-loaded PLGA-SS-PEG nanomedicine was developed. The nanomaterial possesses spherical morphology and admirable biocompatibility. After targeted endocytosis in tumour cells via the selective recognition between EGFR and its aptamer, the PLGA nanomedicine is triggered by a high GSH level and releases its cargo in lung cancer cells. The in vitro and in vivo results reveal that the PLGA nanomedicine not only inhibited the proliferation and promoted the apoptosis of lung cancer cells, but also possessed better therapeutic efficacy and less toxic side effects compared with the free anticancer agent. Consequently, this study provides a novel approach to construct a biodegradable nanomedicine with targeted recognition and stimuli response. Moreover, it inhibited the proliferation of lung cancer cells with high efficiency and low toxicity. Importantly, the PLGA nanomedicine demonstrates encouraging potential as a multifunctional nano-system applicable for cancer therapy.

中文翻译：

载有谷胱甘肽反应且靶向递送的抗癌药负载的PLGA纳米药物可用于治疗肺癌。

刺激反应或控释是纳米医学的新研究热点。然而，关于具有刺激反应的有机纳米药物的研究很少，这限制了它们在生物学上的实际应用。另外，高灵通素（HHT）已被用作有效的抗癌剂，但是降低其毒性和副作用是亟待解决的问题。本文中，开发了EGFR（表皮生长因子受体）适体修饰的负载HHT的PLGA-SS-PEG纳米药物。纳米材料具有球形形态和令人称赞的生物相容性。通过EGFR及其适体之间的选择性识别在肿瘤细胞中进行有针对性的内吞作用后，PLGA纳米药物被高GSH含量触发，并释放其载于肺癌细胞中。体内外实验结果表明，PLGA纳米药物不仅能抑制肺癌细胞的增殖并促进其凋亡，而且与游离抗癌药相比具有更好的治疗效果和更小的毒副作用。因此，这项研究提供了一种新颖的方法来构建具有目标识别和刺激反应的可生物降解的纳米药物。而且，它以高效率和低毒性抑制肺癌细胞的增殖。重要的是，PLGA纳米药物作为适用于癌症治疗的多功能纳米系统显示出令人鼓舞的潜力。这项研究提供了一种新颖的方法来构建具有目标识别和刺激反应的可生物降解的纳米药物。而且，它以高效率和低毒性抑制肺癌细胞的增殖。重要的是，PLGA纳米药物作为适用于癌症治疗的多功能纳米系统显示出令人鼓舞的潜力。这项研究提供了一种新颖的方法来构建具有目标识别和刺激反应的可生物降解的纳米药物。而且，它以高效率和低毒性抑制肺癌细胞的增殖。重要的是，PLGA纳米药物作为适用于癌症治疗的多功能纳米系统显示出令人鼓舞的潜力。

更新日期：2020-01-06

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11